ClinicalTrials.gg
Status unknownNCT01535768Updated Jul 21, 2017

Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

A Phase 4 interventional study of Aqueous Suppressant Eye Drops in Glaucoma, sponsored by Credit Valley EyeCare. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by Credit Valley EyeCare · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing timolol in Glaucoma — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma.

Planned enrollment
8th of 28
150 · median 60
Started
2012
the only one that year
Phase 4
13 of 28
none open now
Registered
13th of 28
by date
Lead sponsor
1 of 28
Credit Valley EyeCare

Among the 28 studies testing timolol in Glaucoma, this one is the 8th largest by planned enrollment, is the only one that started in 2012, is one of 13 in phase 4, and was the 13th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 28 studies testing timolol in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About timolol

Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing timolol in Glaucoma as a file.
02

Study summary

After implantation of an Ahmed glaucoma valve in patients with glaucoma, hyperencapsulation phase is an unwanted postoperative phenomenon, typically occurring with the free 3 months postoperatively. When this does occur, it is treated with aqueous suppressant eye drops.

This study aims to determine if it is possible to reduce the rate of hyperencapsulation phase. Patients in the treatment group will receive aqueous suppressant eye drops before the hyperencapsulation phase starts. Treatment will be initiated once their intraocular pressure is above a pre-defined level, and will target a pre-defined range.

Read the detailed description

Patients with glaucoma requiring tube shunt surgery, with or without simultaneous cataract surgery, will be enrolled in this prospective randomized controlled study at ten sites across Canada and the United States (to be determined). Patients with highly advanced glaucoma at high risk of fixation loss, neovascular glaucoma, chronic uveitis, marked corneal disease, sulfa allergy, renal disease or any contraindication to diamox use will be excluded.

Patients scheduled for Ahmed glaucoma valve surgery, with or without cataract surgery, will be randomized using a stratified central block randomization approach to the treatment group or control group. Those scheduled for combined cataract and tube shunt will be randomized separately from those receiving tube shunt alone. Surgeons will be masked to the postoperative treatment or control group at the time of surgery since randomization will occur when the patient is one-week postoperative Those in the treatment group would receive short-term prophylactic aqueous suppression for the first 3 postoperative months to maintain intraocular pressure (IOP) between 7 and 10mmHg. The control group would not receive prophylactic aqueous suppression, but would be treated using a similar protocol as the treatment group in the event that an Hyperencapsulation phase (HEP) endpoint is met.

Prophylactic aqueous suppression in the study group would only be given for the 1st 3 months postoperatively. At the 3 month visit, aqueous suppression will be stopped. The primary outcome measure is washout IOP at 4 months postoperative. Washout IOP will be checked one month after discontinuation (earlier if needed i.e., advanced glaucoma patients).

Beyond 3 months, aqueous suppressants would be used at the clinician's discretion based on IOP.

At the conclusion of the study, the 4-month postoperative washout IOP, the incidence of HEP, the 12-month IOP, the 13-month washout IOP, and medication requirement would be compared between the treatment and control arms.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of glaucoma
  • scheduled for Ahmed glaucoma valve surgery, with or without simultaneous cataract surgery

Exclusion criteria

Exclusion Criteria:

  • neovascular glaucoma
  • uveitic glaucoma
  • prior tube shunt surgery
  • prior cyclodestruction procedure
  • abnormal cornea that would make IOP measurements unreliable
  • sulfa allergy
  • systemic to acetazolamide use
  • inability to attend follow up visits
  • intraocular pressure greater than 21 at postoperative week 1 (represents primary failure of the valve)
  • anterior chamber fill within the first week postoperatively
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.

    Drug: Aqueous Suppressant Eye Drops

  • No intervention
    Control Group

    Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates. (If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)

Interventions

  • Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID). Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID). Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)

    Also known as: Timoptic, Trusopt, Azopt, Alphagan-P, Xalatan, Travatan Z, Lumigan, Diamox

06

What researchers measure

Primary outcomes

  1. Intraocular pressure

    The primary outcome measure is intraocular pressure (IOP) at 4 months postoperative. This will be a washout IOP (i.e. all glaucoma eye drops will be stopped at 3 months postoperative in all study patients)

    Time frame: 4 months postoperative

Secondary outcomes

  1. Hyperencapsulation phase (HEP)

    The HEP endpoint will be met within the first 3 postoperative months if all of the following are met: 1. IOP increase by 5mmHg or greater compared to previous visit 2. A bleb appearance in keeping with encapsulation (raised, thickened, firm, dome-shaped) 3. no other reason for IOP increase

    Time frame: first 3 months postoperative

  2. Qualified Ahmed Glaucoma Valve success

    An eye will have qualified success of the Ahmed glaucoma valve if the intraocular pressure (IOP) is at or below 18mmHg at 12 months with use of medications.

    Time frame: 12 months

  3. Absolute Ahmed Glaucoma Valve success

    An eye will have absolute success of the Ahmed glaucoma valve if the intraocular pressure (IOP) is at or below 18mmHg at 13 months without use of medications. Medications will be stopped at the 12 month visit, and so eyes will be washed out at 13 months.

    Time frame: 13 months

  4. Number of glaucoma medications

    Will count the number of glaucoma medication classes required to achieve qualified Ahmed Glaucoma Valve success at 12 months.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Credit Valley Eye Care
    Mississauga, Ontario L5L1W8, Canada
    Recruiting
    • Amandeep S Rai, MD · Contactamandeeprai85@gmail.com · 647-987-4724
    • Devesh K Varma, MD FRCSC · Principal investigator
    • Ike K Ahmed, MD FRCSC · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2018 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2012
First posted
Feb 20, 2012
Start
Feb 2012
Primary completionEst.
Jun 2018
CompletionEst.
Jun 2020
Last update
Jul 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01535768
Lead sponsor
Credit Valley EyeCare
Collaborators
Canadian Glaucoma Clinical Research Council
Responsible party
Amandeep Rai (MD, Glaucoma and Advanced Anterior Segment Surgery Research Fellow, Principal Investigator, Credit Valley EyeCare) — Principal investigator
First posted
Feb 20, 2012
Start date
Feb 2012
Primary completion
Jun 2018 (estimated)
Completion
Jun 2020 (estimated)
Last update
Jul 21, 2017

Study contacts

Amandeep S Rai, MD
Contact
amandeeprai85@gmail.com
647-987-4724
Devesh K Varma, MD FRCSC
principal investigator · University of Toronto
Ike K Ahmed, MD FRCSC
principal investigator · University of Toronto
Amandeep S Rai, MD
study director · University of Toronto

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion